Nemaura Medical, a leading medical technology company, has recently announced promising interim results from its metabolic health program. The primary objective of the study was to determine whether a metabolic program incorporating a daily-wear continuous glucose monitor (CGM) could lead to greater engagement levels and sustainable weight reduction compared to other programs.
The study, which was run in collaboration with the UK’s National Health Service, involved the use of Miboko (Mind, Body, Konnect), a program that integrates Nemaura Medical’s non-invasive glucose sensor with their bespoke app, educational content, and AI-driven analytics platform. Participants in the study were invited by their primary care practice based on a BMI over 25, and they were given access to the Miboko app, which allowed them to enter their diet, lifestyle, and weight data on a daily or weekly basis.
Crucially, users also wore the daily-wear CGM sensor every two weeks, which provided real-time glucose tracking and displayed a Metascore®, a measure of glucose variability. Additionally, users received a video report that analyzed their glucose trends and provided personalized diet and lifestyle recommendations based on their Metascore®. These insights proved to be beneficial to the participants, increasing their understanding of food choices, portion sizes, and overall weight loss goals.
The study tracked 83 participants with a mean age of 54, consisting of 67% female and 33% male participants. After 20 weeks of enrollment, 59 individuals recorded weight loss, with 21 participants losing over 5KG (11 pounds). On average, the participants achieved a weight loss of 2.9KG (6.3 pounds), with the rate of change increasing after week 8.
Moreover, the program demonstrated a retention rate of 32.5% after 20 weeks of use, exceeding industry averages for health and wellbeing apps. Participants also expressed a strong likelihood of continuing with the program beyond the study duration. This high level of engagement and satisfaction showcases the effectiveness of the Miboko program in promoting long-term behavioral changes and sustained weight loss.
One of the key advantages of the program is its affordability. Nemaura Medical aims to offer its CGM-embedded program at a significantly lower cost compared to existing alternatives. The integration of their proprietary non-invasive sensor technology allows for reduced sensor costs, as the sensors are only worn a few days each month. This makes a low-cost, metabolic health improvement prevention program commercially accessible to a wider population.
Nemaura Medical plans to publish more detailed results from the study in the near future. The company’s commitment to making metabolic health programs affordable and accessible bodes well for individuals seeking sustainable weight loss solutions. With the successful integration of their CGM sensor, Nemaura Medical is paving the way for innovative and cost-effective approaches to improving metabolic health globally.
